Advertisement


Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance

2024 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

Eleni M. Rettig, MD, of Brigham and Women’s Hospital, discusses the promising but thus far limited data on using circulating tumor HPV DNA for early detection of HPV-related oropharyngeal cancers, which highlights the importance of developing a reliable biomarker (Poster Abstract 177).



Related Videos

Head and Neck Cancer

Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC

Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus carboplatin and paclitaxel. The regimen demonstrated durable antitumor activity, irrespective of patients’ PD-L1 status (Abstract 3).

Head and Neck Cancer

Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer

Pooja Karukonda, MD, of Duke University Medical Center, discusses findings from the PaRTNer study, which addressed the large financial burden faced by patients with head and neck cancer undergoing radiotherapy, particularly older, non-White, female, and low-income patients. Dr. Karukonda discusses some ways to counter this adverse effect (Abstract 13).

Head and Neck Cancer

Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest a durable clinical activity of this combination therapy (Abstract 2).

Head and Neck Cancer

Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer

Samuel Regan, MD, and Benjamin Rosen, PhD, both of the University of Michigan, discuss results from a phase II trial showing the possibility of de-escalating chemoradiation treatment for patients with HPV-related oropharyngeal cancer, based on an FDG-PET imaging biomarker. The data suggest that patients may experience few locoregional recurrences and less toxicity (Abstract 16).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses the results of the NDURE study, which explored the delays in starting postoperative radiation therapy in patients with head and neck cancer and ways to improve the timeliness and equity of treatment. Delays in this therapy are associated with higher recurrence and poorer survival in this population (Abstract LBA2).

Advertisement

Advertisement




Advertisement